8-K Summary
Registrant: Priveterra Acquisition Corp. The provided filing is not identified as an AEON Biopharma, Inc. filing; investors should verify the company identity. The report concerns the company’s initial public offering and related transactions in February 2021. The filing date is February 12, 2021, with events dated February 8 and February 11, 2021.
Business Context and Reporting Period
Priveterra Acquisition Corp. is a special purpose acquisition company (SPAC) that completed its IPO and established a trust account pending an initial business combination. The filing does not report operating results or a financial statement period.
Key Financial and Capital Markets Metrics
- The IPO consisted of 27,600,000 units priced at $10.00 per unit, generating gross proceeds of $276.0 million.
- Each unit included one Class A common share and one-third of a redeemable warrant. Each whole warrant is exercisable at $11.50 per share, subject to adjustment.
- The sponsor privately purchased 5,213,333 warrants at $1.50 per warrant, generating gross proceeds of $7.82 million.
- The filing states that $276.0 million was placed in a U.S.-based trust account. This consisted of $270.48 million from the IPO, including a $9.66 million deferred underwriting discount, and $5.52 million from the private placement warrants.
- No revenue, operating profit, net income, cash flow, margins, or debt metrics are reported.
Material Changes and Transactions
- The company entered into underwriting, warrant, trust, registration rights, sponsor services, and related agreements in connection with the IPO.
- Private placement warrants generally have transfer restrictions, may be exercised on a cashless basis while held by the sponsor or permitted transferees, are not redeemable by the company while so held, and carry registration rights.
- Three independent directors—Julie B. Andrews, James Lightman, and Lance A. Berry—were appointed. Ms. Andrews chairs the Audit Committee; Mr. Berry chairs the Compensation Committee.
- The company adopted its Second Amended and Restated Certificate of Incorporation.
Outlook, Risks, and Unusual Items
- The trust funds are generally restricted until the earliest of completion of an initial business combination, specified redemptions related to charter amendments, or redemption if a business combination is not completed within the applicable deadline.
- The filing states that the company must complete its initial business combination within 24 months of the IPO closing, subject to the charter provisions. If it cannot complete a business combination within 18 months, public shares are subject to redemption, subject to applicable law.
- The filing provides no target company, transaction terms, operating guidance, or forecast.
- The filing contains an apparent timing inconsistency: it is headed with a February 8, 2021 report date, states that the IPO closed on February 11, 2021, and was signed on February 12, 2021.
Facts Investors Should Verify
- Confirm that this filing belongs to Priveterra Acquisition Corp. rather than AEON Biopharma, Inc.
- Verify the IPO closing date, trust-account funding, deferred underwriting discount, and applicable business-combination deadlines.
- Review the warrant agreement for exercise, redemption, adjustment, and cashless-exercise provisions.
- Assess the sponsor’s private placement warrant rights and transfer restrictions.
- Review the amended charter and trust agreement for redemption rights and the consequences of failing to complete a business combination.